Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer

Joohyun Hong and Yeon Hee Park

Abstract: Although human epidermal growth factor receptor 2 (HER2)-positive breast cancer was associated with poor prognosis, it has been changed after the development of trastuzumab. There has been great progress in perioperative HER2-targeting treatment, and investigations of several novel drugs and their combinations are ongoing. Adjuvant trastuzumab with or without pertuzumab for 1 year in combination with concomitant chemotherapy has become a standard treatment in high-risk node-negative tumors or node-positive HER2-positive early breast cancer patients without residual disease or who have not received neoadjuvant treatment. For low-risk HER2-positive early breast cancer patients, adjuvant paclitaxel and 1-year trastuzumab are possible alternatives. For residual disease after neoadjuvant treatment, adjuvant trastuzumab emtansine (T-DM1) for 14 cycles is a standard treatment. Non-anthracycline chemotherapy with dual anti-HER2 targeting of trastuzumab and pertuzumab represents one of the preferred neoadjuvant regimens to achieve higher pathologic complete response (pCR) rates and better clinical outcomes. Further research is needed to develop and validate potential biomarkers to predict pCR, which could help escalate or de-escalate anti-HER2 therapy. Trials incorporating novel agents such as T-DM1, trastuzumab deruxtecan (T-DXd), and immune checkpoint inhibitors and trying to de-escalate treatments in neoadjuvant setting are ongoing. In the future, tailored treatments such as no adjuvant therapy, various HER2-directed therapies alone with chemotherapy, combinations of various HER2-directed therapies and chemotherapy, addition of immune checkpoint inhibitors, and omission of surgery will be individualized in HER2-positive early breast cancer patients.

Keywords: adjuvant therapy, early breast cancer, HER2+ breast cancer, HER2-targeted therapy, neoadjuvant therapy

Received: 7 January 2022; revised manuscript accepted: 25 May 2022.

Introduction

Human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family of transmembrane receptor kinases, of which there is amplification or overexpression in 20–30% of invasive breast cancers. HER2 amplification and overexpression are associated with metastasis, relapse, and reduced survival.1,2 HER2-positive breast cancer treatment is a model of successful treatment progress based on trastuzumab. With the development of trastuzumab, there has been great progress in perioperative HER2-targeting treatment, and investigations of several novel drugs and their combinations are ongoing.

Adjuvant HER2 treatment

Adjuvant trastuzumab

Trastuzumab is a humanized monoclonal antibody targeting the extracellular domain of HER2. Either alone or in conjunction with chemotherapy, it has shown efficacy in first-line treatment of HER2-overexpressing metastatic breast cancer.5,4 In addition to its efficacy in the metastatic setting, it has shown efficacy in adjuvant settings.5-7 In a
joint analysis of NSABP B-31 and NCCTG N9831, 52 weeks of adjuvant trastuzumab combined with paclitaxel following doxorubicin and cyclophosphamide improved clinical outcomes including disease-free survival (DFS) and overall survival (OS) compared to the chemotherapy-only group in surgically removed and node-positive or high-risk node-negative [tumor size greater than 2 cm if positive for estrogen or progesterone receptors or greater than 1 cm if negative for both hormone receptors (HRs)] HER2-positive breast cancer patients.7 This benefit of additional adjuvant trastuzumab in early-stage HER2-positive breast cancer patients persisted in a subsequent analysis with median follow-up of 8.4 years.8 In the latest meta-analysis of 13,864 patients, where the median follow-up was 10.7 years, trastuzumab in addition to chemotherapy in early-stage HER2-positive breast cancer patients consistently reduced recurrence and mortality rates.9

In the HERA trial, node-positive or high-risk node-negative (tumor size larger than 1 cm) HER2-positive breast cancer patients who had completed locoregional therapy and neoadjuvant or adjuvant chemotherapy were randomly assigned to trastuzumab for 2 years, trastuzumab for 1 year, or observation. Trastuzumab for 1 year significantly improved DFS compared with observation.6 After a median follow-up of 11 years in this trial, the benefit of 1-year trastuzumab in terms of DFS persisted compared with observation. However, 2-year trastuzumab did not show additional benefit compared to 1-year trastuzumab.10

In contrast, sequential 1-year trastuzumab after adjuvant anthracycline-based chemotherapy with or without docetaxel in axillary node- and HER2-positive breast cancer patients was not associated with a significant increase in 3-year DFS compared to the observation group in the FNCLCC-PACS 04 trial.11 However, DFS was significantly higher in the trastuzumab group than in the observation group in the per-protocol populations after a median follow-up of 115 months, even though OS was not different.12

In the BCIRG-006 trial, node-positive or high-risk node-negative HER2-positive early-stage breast cancer patients were randomly assigned to receive doxorubicin and cyclophosphamide followed by docetaxel (AC-T), AC-T plus 52 weeks of trastuzumab (AC-TH), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH) for adjuvant treatment.13 The addition of 1-year trastuzumab improved DFS and OS compared with the no trastuzumab group, as shown in other clinical trials. While there were no significant differences in DFS and OS between the trastuzumab-containing arms, cardiac toxicities such as congestive heart failure were significantly less frequent in the non-anthracycline arm (TCH) compared to AC-TH. A long-term follow-up of a median of 10.3 years demonstrated the persistent benefit of additional adjuvant trastuzumab and lower cardiac toxicities in the non-anthracycline arm (TCH) compared to AC-TH.14 As not only anthracycline, but also trastuzumab could provoke adverse cardiac events, trastuzumab with non-anthracycline-containing chemotherapy would be an effective alternative, especially for patients at greater risk of cardiac toxicities such as those with a pre-existing cardiac problem, obesity, or prior exposure to anthracyclines.

The analysis of NSABP B-31/NCCTG N9831, HERA, and BCIRG-006 trials described above included only node-positive or large tumor patients, which is a high-risk disease, and there were no randomized trials of patients with node-negative or smaller tumors. However, three retrospective analyses demonstrated significantly higher risk of relapse in HER2-positive small, node-negative tumors compared with HER2-negative disease.15–17 Another retrospective analysis showed significant recurrence-free survival, invasive disease-free survival (IDFS), and OS benefits of adjuvant trastuzumab compared with no trastuzumab in small or node-negative HER2-positive breast cancer patients.18 In accordance with previous results, a prospective APT trial evaluated adjuvant paclitaxel and trastuzumab in low-risk (tumor size no greater than 3 cm with node-negative disease or one lymph node micrometastasis if an axillary dissection was completed and no further lymph node involvement was identified) HER2-positive breast cancer patients. In the APT trial, adjuvant paclitaxel and trastuzumab showed excellent prognosis, with a 3-year IDFS of 98.7% and 7-year DFS of 93% in low-risk HER2-positive breast cancer patients.19,20 Despite this outstanding outcome, adjuvant paclitaxel and trastuzumab in low-risk HER2-positive breast cancer patients would be interpreted not as de-escalating therapy, but escalating therapy considering its good prognosis.21

In addition to efforts to de-escalate chemotherapy regimens, there have been several trials to reduce...
The duration of treatment. Although the standard period of adjuvant trastuzumab has been 1 year, there have been several trials shortening this period (Table 1). In the SOLD trial and Short-HER trial, 9-week adjuvant trastuzumab treatment for HER2-positive breast cancer patients failed to prove non-inferiority over that for 12 months. However, cardiac toxicity was less frequent in the 9-week groups.22,23 In the PHARE and HORG trials, 6-month adjuvant trastuzumab for HER2-positive breast cancer patients failed to demonstrate non-inferiority over 12-month treatment.24,25 Contrary to these four failed trials, 6-month adjuvant trastuzumab fulfilled non-inferiority over 12 months in 4-year DFS in the PERSEPHONE trial.26 However, interpretation of the PERSEPHONE results should be cautious because all the other trials with a shortened period of adjuvant trastuzumab failed. If the non-inferiority margin was narrower in the PERSEPHONE trial, as in the other trials, the result of the PERSEPHONE trial would not have been statistically significant.27 Although the shorter 6-month duration of adjuvant trastuzumab might be appropriate in a specific population, as in the PERSEPHONE trial, this should be decided carefully on a per-patient basis under meticulous consideration including the risk of

Table 1. Comparison of trials trying to reduce duration of trastuzumab.

| Trials     | Duration of trastuzumab | Number of patients | Node negative (%) | Hormone receptor positive (%) | Concomitant trastuzumab (%) | Efficacy (versus 1-year trastuzumab) | Cardiac events (versus 1-year trastuzumab) |
|------------|-------------------------|-------------------|------------------|-------------------------------|-----------------------------|-------------------------------------|------------------------------------------|
| SOLD       | 9 weeks                 | 2174              | 59.6             | 66*                           | 100                         | 5-year DFS 88% versus 90.5% HR 1.39; 90% CI 1.12–1.72 (non-inferiority margin 1.3) | 2% versus 3.9%                          |
| Short-HER  | 9 weeks                 | 1253              | 53.6             | 68.1                          | 100                         | 5-year DFS 85% versus 88% HR 1.13; 90% CI 0.89–1.42 (non-inferiority margin 1.29) | 4.3% versus 13.1%                       |
| PHARE      | 6 months                | 3380              | 54.5             | 60.9                          | 56.3                        | 2-year DFS 91.1% versus 93.8% HR 1.28; 95% CI 1.05–1.56 (non-inferiority margin 1.15) | 1.9% versus 5.7%                        |
| HORG       | 6 months                | 481               | 21               | 66.7                          | 100                         | 3-year DFS 93.3% versus 95.7% HR 1.57; 95% CI 0.86–2.1 (non-inferiority margin 1.53) | 0.8% versus 0%                          |
| PERSEPHONE | 6 months                | 4088              | 58.3             | 69.1*                         | 46.6                        | 4-year DFS 89.4% versus 89.8% HR 1.07; 90% CI 0.93–1.24 (non-inferiority margin 1.32) | 7.8% versus 11.4%**                     |

All trials randomized, non-inferiority.
*SOLD, PERSEPHONE ER-positive.
**Clinical cardiac dysfunction.
CI, confidence interval; DFS, disease-free survival; HR: hazard ratio.
recurrence as well as side effects and cost-effectiveness.

Adjuvant dual anti-HER2 treatment with trastuzumab

Other anti-HER2 agents were added to 1-year adjuvant trastuzumab to try to improve the outcomes. Lapatinib is a small molecule that reversibly inhibits tyrosine kinases of HER2 and epidermal growth factor receptor (EGFR). After additional lapatinib on capecitabine had proven to have a significant progression-free survival (PFS) benefit in HER2-positive advanced breast cancer patients compared to capecitabine alone, lapatinib in combination with capecitabine has been a therapeutic option for HER2-positive advanced breast cancer patients who progressed after trastuzumab-containing chemotherapy. In the ALTTO trial, node-positive or high-risk node-negative (tumor size greater than 1 cm) HER2-positive early breast cancer patients were randomized to receive adjuvant treatment with trastuzumab alone, trastuzumab and lapatinib in combination, or trastuzumab followed by lapatinib for 52 weeks. However, lapatinib in addition to trastuzumab did not significantly improve DFS.29

Neratinib is a small-molecule, irreversible tyrosine kinase inhibitor of EGFR, HER2, and HER4. It has shown efficacy in HER2-positive advanced breast cancer patients and improved efficacy in early breast cancer patients. In the ExteNET trial, 1 year of oral neratinib was administered to early breast cancer patients who had completed neoadjuvant or adjuvant trastuzumab-based therapy. One additional year of extended adjuvant therapy with neratinib significantly increased 2-year IDFS to 93.9% compared with 91.6% in the placebo group. This benefit persisted after a median follow-up of 5.2 years, with a 5-year IDFS of 90.2% in the neratinib arm compared to 87.7% in the placebo group. Especially in HR-positive patients in whom neratinib was given within 1 year of prior trastuzumab, a significant 5-year IDFS benefit was shown. In addition, a similar trend was observed in high-risk patients with residual disease after neoadjuvant treatment. Consequently, adjuvant neratinib following trastuzumab within 1 year is considered for high-risk HR-positive/HER2-positive breast cancer patients. Diarrhea was the most common side effect of neratinib, with 40% of patients experiencing grade 3 diarrhea and 17% discontinuing the drug due to diarrhea. However, preemptive prophylaxis with loperamide, budesonide, and colestipol, alone or in combination, and dose escalation of neratinib reduced the occurrence of neratinib-related diarrhea.35

Pertuzumab is another HER2-targeting monoclonal antibody that binds HER2 at a different epitope of the extracellular domain and prevents HER2 from dimerizing with other HER receptors. In the CLEOPATRA trial, pertuzumab plus trastuzumab plus docetaxel significantly prolonged PFS and OS compared to trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients. From this promising effect in the metastatic setting, this dual anti-HER2 targeting was attempted in an adjuvant setting. In the APHINITY trial, node-positive or high-risk node-negative (tumor size greater than 1 cm or greater than 0.5 cm in the presence of a high-risk feature such as histologic or nuclear grade 3 or HR negativity) HER2-positive early breast cancer patients were randomized to receive pertuzumab or placebo and trastuzumab plus chemotherapy (anthracyclines, cyclophosphamide followed by taxanes or docetaxel plus carboplatin). Adjuvant dual anti-HER2 targeting with pertuzumab and trastuzumab significantly improved 3-year IDFS without increasing cardiac toxicities. Subsequent analysis with a 74-month median follow-up confirmed this IDFS benefit, especially in the node-positive group and HR-positive group. A longer follow-up, up to 15 years, is ongoing to fully evaluate the OS benefit. From these results, adjuvant pertuzumab and trastuzumab with chemotherapy is a standard of care in node-positive HER2-positive breast cancer in the latest National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines as of 2021.

Adjuvant T-DM1

T-DM1 is an antibody–drug conjugate of HER2-targeting trastuzumab and emtansine, which is a cytotoxic microtubule inhibitor. In addition to the antitumor effect of trastuzumab, release of a cytotoxic microtubule inhibitor has an additional antitumor effect when this agent approaches target cells bearing HER2 with trastuzumab. After its efficacy was proven in metastatic HER2-positive breast cancer, it showed better efficacy than trastuzumab in an adjuvant setting of residual invasive HER2-positive breast cancer. In the KATHERINE trial, early breast cancer
patients with residual disease after taxane-based neoadjuvant therapy with trastuzumab were randomly assigned to receive T-DM1 or trastuzumab for 14 cycles.47 Three-year IDFS was significantly better in the T-DM1 group than in the trastuzumab group (hazard ratio 0.5, \( p < 0.001 \)). In a subgroup analysis from the KATHERINE trial, the benefit of 3-year IDFS with T-DM1 was consistent regardless of tumor HR status or adjuvant radiotherapy, while that of patients receiving trastuzumab with negative HR showed the worst IDFS. However, given the hazard ratio of 0.66 is higher in the subgroup including ypT0, ypT1mic, and ypTis than in subgroups without ypT0, ypT1mic, or ypTis (hazard ratio of 0.29 in ypT4 subgroup, 0.34 in ypT1, ypT1c, 0.4 in ypT3, and 0.5 in ypT2), adjuvant T-DM1 might be skipped in cases with little to no residual cancer burden (RCB). Although 8.3% of HER2-positive patients in pre-neoadjuvant biopsy were HER2 negative on retesting of surgical sample data, a similar better result of T-DM1 versus trastuzumab was shown.48 Subsequent subgroup analysis revealed the benefit of T-DM1 across patient subgroups, including high-risk tumors and small tumors. T-DM1 also did not increase the overall risk of central nervous system recurrence compared to the trastuzumab group. Moreover, T-DM1 showed consistent efficacy regardless of type of neoadjuvant chemotherapy.49 Based on these results, adjuvant T-DM1 is a standard of care in residual HER2-positive breast cancer patients after neoadjuvant treatment and surgery in the latest NCCN and ESMO guidelines as of 2021.41,42

The ATEMPT trial compared adjuvant T-DM1 versus adjuvant paclitaxel and trastuzumab in low-risk (tumor size smaller than 2 cm and node negative or one lymph node with micrometastasis) HER2-positive breast cancer patients, which is a current standard in early HER2-positive breast cancer patients based on the results of the APT trial as described above, regarding toxicity profile and efficacy. Although 1 year of adjuvant T-DM1 showed 97.8% 3-year IDFS, clinically relevant toxicity of T-DM1 was similar to that of adjuvant paclitaxel and trastuzumab and failed to demonstrate reduced toxicity of T-DM1.50

Dual anti-HER2 treatment with T-DM1 and pertuzumab was also tried. In the KAITLIN trial, node-positive or high-risk node-negative (tumor size larger than 2 cm and HR negative) HER2-positive breast cancer patients were randomly assigned to anthracycline-based chemotherapy followed by 18 cycles of T-DM1 plus pertuzumab or taxane and trastuzumab plus pertuzumab.51 However, it failed to show a benefit in 3-year IDFS rate.

Concurrent adjuvant endocrine therapy

HR-positive/HER2-positive and HR-negative/HER2-positive breast cancers are two different biological subgroups that have distinct natural courses, responses to treatment, and clinical outcomes.52 Although HR-negative/HER2-positive breast cancer has worse DFS compared with HR-positive/HER2-positive breast cancer with or without anti-HER2 treatment, adjuvant trastuzumab reduces the risk of relapse in HER2-positive breast cancer regardless of HR status.53 In addition, HR-negative/HER2-positive breast cancer patients are likely to have a slightly higher response to anti-HER2 treatment compared with HR-positive/HER2-positive patients.

In the SOFT and TEXT trials of premenopausal and HR-positive/HER2-positive early breast cancer patients, tamoxifen plus ovarian suppression improved DFS and OS compared with tamoxifen alone.54 There was no difference in DFS between tamoxifen and aromatase inhibitor groups in the latest meta-analysis including premenopausal and postmenopausal HR-positive/HER2-positive early breast cancer patients.55 However, not all patients in these analyses received anti-HER2 treatment because it was not the standard of care at that time.

Concurrent adjuvant endocrine therapy with anti-HER2 treatment is the current standard of care for HR-positive/HER2-positive breast cancer patients. Additional research is needed to determine optimal hormone therapy with anti-HER2 treatment.

In conclusion, adjuvant trastuzumab with or without pertuzumab for 1 year in combination with concomitant chemotherapy has become a standard treatment in high-risk node-negative tumors or node-positive HER2-positive early breast cancer patients without residual disease or who have not received neoadjuvant treatment. In particular, adjuvant trastuzumab with pertuzumab is the standard of care for node-positive patients. The risk of cardiac toxicities should be considered when administering trastuzumab, especially with anthracycline-containing chemotherapy. For low-risk HER2-positive early breast
cancer patients, adjuvant paclitaxel and 1-year trastuzumab are possible alternatives. For residual disease after neoadjuvant treatment, adjuvant T-DM1 for 14 cycles is a standard treatment. Adjuvant endocrine therapy is added for HR-positive/HER2-positive early breast cancer.

**Neoadjuvant HER2 treatment**

Neoadjuvant chemotherapy for breast cancer became routine practice due to several advantages. Neoadjuvant chemotherapy provided an opportunity for breast conserving surgery rather than modified radical mastectomy and sentinel lymph node biopsy without extensive lymph node dissection. Specifically, a pathologic complete response (pCR) has become a successful surrogate marker that has a correlation with event-free survival (EFS), DFS, and OS, especially in HER2-positive (non-luminal) and triple-negative tumors. These two subtypes were also associated with higher pCR rates to neoadjuvant chemotherapy in a meta-analysis. Consequently, many trials were conducted to achieve higher pCR rates for better outcomes in HER2-positive breast cancer (Figure 1).

**Neoadjuvant trastuzumab**

In the NOAH trial, neoadjuvant chemotherapy with trastuzumab doubled the pCR rate compared with that of neoadjuvant chemotherapy alone in HER2-positive locally advanced or inflammatory breast cancer (38% versus 19%, p = 0.001). The neoadjuvant chemotherapy regimens consisted of doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and fluorouracil. The benefit of pCR-associated EFS was sustained in the additional trastuzumab group in the longer term follow-up analysis.

**Neoadjuvant dual anti-HER2 treatment with trastuzumab**

Other anti-HER2 agents were added to trastuzumab to achieve higher pCR rates in the neoadjuvant setting.

---

**Figure 1.** Summary of pCR rates for several trials of HER2-directed therapy. tpCR in NOAH, ypT0 ypN0 in TRYPHAENA. C, cyclophosphamide; Cb, carboplatin; D, doxorubicin; dd, dose dense; Doc, docetaxel; E, epirubicin; F, fluorouracil; H, trastuzumab; HER2, human epidermal growth factor receptor 2; K, trastuzumab emtansine (T-DM1); L, lapatinib; Ld, liposomal doxorubicin; M, methotrexate; P, pertuzumab; pCR, pathologic complete response; T, paclitaxel.

1. Gianni L, et al. Lancet 2010; 2. José B, et al. Lancet 2012; 3. Valentina G, et al. J Clin Oncol 2016; 4. Lisa AC, et al. J Clin Oncol 2016; 5. Gianni L, et al. Lancet Oncol 2012; 6. Schneeweiss A, et al. Ann Oncol 2013; 7. Loibl S, et al. Ann Oncol 2017; 8. Nitz UA, et al. Ann Oncol 2017; 9. Swain SM, et al. Eur J Cancer 2019; 10. van Ramshorst MS, et al. Lancet Oncol 2018; 11. Schneeweiss A, et al. Eur J Cancer 2019; 12. José Manuel P, et al. Lancet Oncol 2021; 13. Thomas H, et al. JAMA Oncol 2021; 14. Amy S, C, et al. Nat Commun 2021; 15. Sara AH, et al. Lancet Oncol 2018.
Lapatinib was tried in neoadjuvant-setting trials. In the NeoALTTO trial, neoadjuvant chemotherapy with lapatinib and trastuzumab showed a higher pCR rate compared with neoadjuvant chemotherapy with either trastuzumab or lapatinib (46.8% versus 27.6% versus 20%, \( p = 0.0007 \)). However, this benefit did not extend to significantly better clinical outcomes of 6-year EFS and OS in a subsequent analysis. Similar results were found in the CHER-LOB trial. Although a significantly higher pCR rate was achieved in the combined lapatinib and trastuzumab group than in the trastuzumab or lapatinib alone groups, the combined lapatinib and trastuzumab group showed a better trend only in 9-year recurrence-free survival. In contrast, the results of neoadjuvant chemotherapy with lapatinib and trastuzumab opposed the results in the CALGB 40601 trial. Although the pCR rate was higher with combined lapatinib and trastuzumab than with trastuzumab alone, the difference was not significant. However, relapse-free survival and OS at 7 years were significantly improved with combined lapatinib and trastuzumab compared with trastuzumab. In conclusion, dual anti-HER2 targeting with lapatinib and trastuzumab in the neoadjuvant setting showed inconsistent results.

Pertuzumab was also added to trastuzumab in several neoadjuvant-setting trials that included patients with HER2-positive, operable, locally advanced, or inflammatory breast cancer with primary tumors larger than 2 cm. In the NeoSphere trial, pertuzumab and trastuzumab plus docetaxel had a significantly improved pCR rate of 39.3% compared with trastuzumab plus docetaxel, pertuzumab plus docetaxel, or pertuzumab plus trastuzumab, which also showed a correlation with 5-year PFS and DFS. In the TRYPHAENA trial, patients were randomized to receive 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by docetaxel (T) with trastuzumab and pertuzumab (HP) concurrent with FEC and docetaxel (Arm A: FECHP \( \rightarrow \) THP) or with docetaxel (Arm B: FEC \( \rightarrow \) THP); or docetaxel, carboplatin with trastuzumab and pertuzumab (Arm C: TCHP). The pCR rates were promising (61.6% (Arm A), 57.3% (Arm B), and 66.2% (Arm C)), and cardiac toxicity was low even in the antracycline-containing dual anti-HER2 treatment arms (Arm A and Arm B). Long-term DFS and PFS were similar among treatment arms, and pCR was associated with DFS. In the BERENICE trial, patients were randomized to receive either 5-fluorouracil and cyclophosphamide followed by paclitaxel or FEC followed by docetaxel and pertuzumab and trastuzumab concurrent with taxanes. The groups demonstrated similar pCR rates (above 60%), and cardiac toxicity was low. In the final analysis, 5-year EFS and OS were similar between the two groups, reaching around 90% and 95%, respectively. Many trials using dual anti-HER2 therapy with pertuzumab and trastuzumab in the neoadjuvant setting have shown pCR rates around 60% or greater, while cardiac toxicity was rare and toxicity was well managed. Among them, the TRAIN-2 trial evaluated the neoadjuvant backbone chemotherapy regimens while administering concurrent trastuzumab and pertuzumab in stage II–III HER2-positive breast cancer patients. These regimens consisted of FEC followed by paclitaxel and carboplatin or paclitaxel and carboplatin without anthracycline. While pCR rates between antracycline and non-antracycline groups were similar, grade 3 or worse febrile neutropenia was more frequent in the antracycline group. In a subsequent analysis, 3-year EFS and OS were similar, demonstrating that trastuzumab and pertuzumab with antracycline-omitting chemotherapy can be considered.

Neoadjuvant dual blockade with trastuzumab and pertuzumab plus weekly paclitaxel for 12 weeks showed a pCR rate of 90.5% in the WSG-ADAPT HER2+/HR- phase II trial. In the PHERGain trial, dual anti-HER2 agents of trastuzumab and pertuzumab with or without docetaxel and carboplatin were given neoadjuvantly for two cycles to HER2-positive stage I–IIIA, invasive, operable breast cancer patients using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (F-PET/CT) to identify the response. Although trastuzumab and pertuzumab with chemotherapy showed significantly better pCR rates than the trastuzumab and pertuzumab group, pCR rates between F-PET/CT responders and non-responders in the trastuzumab and pertuzumab group were not significantly different (37.9% in F-PET/CT responders versus 25.9% in F-PET/CT non-responders, \( p = 0.068 \)), demonstrating a possibility of de-escalating or escalating neoadjuvant treatment depending on F-PET/CT response.

**Neoadjuvant T-DM1**

Neoadjuvant T-DM1 was administered solely without chemotherapy in the PREDIX HER2 trial. HER2-positive breast cancer patients with tumors larger than 2 cm or lymph node
Metastases were randomized to receive T-DM1 alone or docetaxel, trastuzumab, and pertuzumab. Neoadjuvant T-DM1 alone showed comparable pCR with a more favorable toxic profile.

T-DM1 was also tested in dual anti-HER2 therapy regimens. In the I-SPY2 trial, stage II or III HER2-positive breast cancer patients, with tumor size larger than 2.5 cm, were randomized to receive either T-DM1 plus pertuzumab; paclitaxel, trastuzumab, and pertuzumab; or paclitaxel and trastuzumab; all three groups were followed by doxorubicin/cyclophosphamide. Both the T-DM1 plus pertuzumab group and the paclitaxel, trastuzumab, plus pertuzumab group showed significantly better pCR rates than the paclitaxel and trastuzumab group. However, when comparing T-DM1 plus pertuzumab with a regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab in the KRISTINE trial, neoadjuvant systemic chemotherapy with trastuzumab and pertuzumab resulted in a significantly higher pCR rate than did T-DM1 plus pertuzumab (pCR rate of 55.7% versus 44.4%, p = 0.016). In subsequent analysis, the 3-year EFS was consistently worse in the group who received T-DM1 plus pertuzumab than in the systemic chemotherapy with trastuzumab and pertuzumab group. Because HER2 heterogeneity might influence the lower pCR rate in the T-DM1 plus pertuzumab group, it should be considered when administering T-DM1 plus pertuzumab without conventional chemotherapy.

Neoadjuvant atezolizumab
Incorporating atezolizumab in neoadjuvant treatment is under investigation. In the Impassion050 trial, neoadjuvant atezolizumab or placebo was administered with dual anti-HER2 treatment and chemotherapy in HER2-positive breast cancer patients who have a very high risk of recurrence. Because atezolizumab showed an unfavorable risk-benefit profile compared with placebo, the trial terminated early.

Biomarkers for predicting pCR
Because pCR is a surrogate marker for EFS, DFS, and OS in HER2-positive breast cancer, there have been many efforts to identify biomarkers to predict pCR (Table 2). However, none have been validated for use in a real-world setting. Further research is needed to develop and validate potential biomarkers.

PIK3CA mutation was significantly associated with lower pCR rate among HER2-positive breast cancer patients in a meta-analysis, mainly in HR-positive and dual anti-HER2 treatment population. However, this lower pCR rate did not extend to meaningfully worse DFS. Considering this, although PIK3CA could be a potential biomarker for predicting pCR, further research is needed for validation and to develop novel treatments such as PI3K inhibitors to increase the pCR rate.

Tumor-infiltrating lymphocytes (TILs) have been another potential biomarker predicting pCR in HER2-positive breast cancer patients receiving neoadjuvant treatment. In one meta-analysis, higher baseline TILs were significantly associated with higher pCR rate regardless of anti-HER2 agents and chemotherapy. In other studies, changes in TILs between baseline and post-neoadjuvant treatment were emphasized even though results were incompatible. Although the magnitude of decrease in TIL was strongly related to pCR in one study, the immune-enriched group (an increase in TIL level from \(< 10\%\) to \(> 10\%\), or a persistent level \(> 10\%\)) achieved significantly higher pCR, EFS, and OS rates compared with the immune-poor group (a decrease in TIL from \(> 10\%\) to \(< 10\%\), or a persistent level \(< 10\%\)).

In another study including all subtypes of early breast cancer, increases in TILs and CD 8+ T cells in response to neoadjuvant chemotherapy were associated with pCR, and on-treatment immune response was more predictive of outcome than baseline immune features, although both were strongly correlated. Therefore, further studies are needed before TILs can be used as a precise biomarker for predicting treatment response.

The HER2-enriched subtype was significantly associated with pCR in all patients regardless of HR status in one meta-analysis. Moreover, chemotherapy-free anti-HER2 neoadjuvant therapy provided significantly higher pCR in the HER2-enriched subtype in this analysis. This suggests that HER2-enriched subtype is a biomarker to de-escalate neoadjuvant anti-HER2 treatment. In another study, HER2-enriched subtype and ERBB2 expression were combined and the HER2-enriched and ERBB2-high group showed higher pCR compared with other groups, which suggests that combining HER2-enriched...
Table 2. Biomarkers for predicting pCR.

| Biomarkers                      | Outcomes              | Limitation and note                                                                 |
|--------------------------------|-----------------------|-------------------------------------------------------------------------------------|
| PIK3CA mutation                | Lower pCR             | Lower pCR not extended to meaningfully worse DFS                                     |
| TILs                           |                       | Conflicting outcomes                                                                |
| Higher baseline TILs           | Higher pCR            |                                                                                     |
| Decrease in TIL                | Higher pCR            |                                                                                     |
| Immune-enriched group          | Higher pCR, EFS, and OS|                                                                                     |
| HER2-enriched subtype          | Higher pCR            | Regardless of HR status and chemotherapy containing                                 |
| Early response                 | Higher pCR            | Early response defined as decrease more than 30% of Ki-67 or low cellularity (<500 invasive tumor cells) in the 3-week biopsy |
| RNA expression signatures      |                       | Distinct gene signatures associated with pCR versus IDFS                            |
| ERBB2                          | Higher pCR            |                                                                                     |
| Estrogen receptor pathway      | Higher pCR and IDFS   | More prominent in chemotherapy-free arm regarding IDFS                               |
| signaling                      |                       |                                                                                     |
| PTEN                           | Lower pCR             |                                                                                     |
| BRCA                           | Lower IDFS            |                                                                                     |
| Immune response                | Higher IDFS           | More prominent in chemotherapy-free arm                                             |

The impact of RNA expression signatures for pCR and survival was also described in the same

subtype and ERBB2 mRNA into a single assay could also produce a potential biomarker for de-
escalating neoadjuvant therapy. In contrast, there was no pCR in the low HER2 expression
(immunohistochemistry 1+/2+ and fluorescence in situ hybridization positive) or basal-like sub-
types in patients with dual anti-HER2 treatment alone in one study.97

Early response, which was defined as a decrease in more than 30% in Ki-67 or low cellularity (<500 invasive tumor cells) on 3-week biopsy, is another possible biomarker for predicting pCR. In the dual anti-HER2 treatment alone arm in the WSG-ADAPT HER2+/HR- phase II trial described above, the pCR rate for non-responders was only 8.3% compared with 44.7% in responders.

In summary, non-anthracycline chemotherapy with dual anti-HER2 targeting of trastuzumab and pertuzumab represents one of the preferred neoadjuvant regimens to achieve higher pCR rates and better clinical outcomes. Anthracycline-containing chemotherapy with trastuzumab and pertuzumab would be an alternative.
Future perspectives
To improve outcomes in HER2-positive early breast cancer, incorporating new agents such as T-DXd and immunotherapy in adjuvant and neoadjuvant settings is under investigation. In addition, given the benefit and toxicity from anti-HER2 treatment and chemotherapy, continuous efforts to de-escalate neoadjuvant and adjuvant treatments or to select specific patients for escalated neoadjuvant and adjuvant treatments are ongoing (Table 3).

T-DXd
T-DXd is another antibody–drug conjugate of HER2-targeting trastuzumab and deruxtecan; it is a topoisomerase I inhibitor linked by a cleavable peptide. T-DXd has an antitumor effect attributed not only to trastuzumab and release of deruxtecan into HER2-bearing cancer cells via trastuzumab, but also to a bystander killing effect due to its highly membrane-permeable characteristics compared to T-DM1. In the DESTINY-Breast01 trial, T-DXd showed durable antitumor activity in HER2-positive metastatic breast cancer patients who received T-DM1. In the DESTINY-Breast03 trial, T-DXd showed significantly better PFS and overall response rate than did T-DM1 in HER2-positive metastatic breast cancer patients treated with trastuzumab and taxane. Following the promising results of T-DXd in HER2-positive metastatic breast cancer patients, there is an ongoing trial evaluating T-DXd in high-risk HER2-positive breast cancer patients with residual invasive disease following neoadjuvant therapy compared with T-DM1, which is the current standard (NCT04622319, DESTINY-Breast05 trial). In addition to adjuvant T-DXd, a phase III trial of neoadjuvant T-DXd is ongoing in locally advanced or inflammatory HER2-positive breast cancer patients (NCT05113251, DESTINY-Breast11 trial). This trial compares eight cycles versus four cycles of neoadjuvant T-DXd, followed by only paclitaxel and trastuzumab plus pertuzumab or four cycles anthracycline and cyclophosphamide before paclitaxel and trastuzumab plus pertuzumab.

Immunotherapy
In this era of immune-oncology, ongoing trials are exploring adding immune checkpoint inhibitors in perioperative HER2-positive breast cancer. Atezolizumab, an anti-programmed cell death-ligand 1 inhibitor, is under investigation with T-DM1. Although adjuvant T-DM1 improved outcomes in residual invasive disease, certain patient groups including inoperable disease and HR-negative and node-positive disease are still at risk of recurrence. To improve this medically unmet need, one study is evaluating adjuvant atezolizumab or placebo and T-DM1 in HER2-positive breast cancer patients with residual disease following neoadjuvant treatment and surgery (NCT04873362, Astefania trial).

Another trial applied neoadjuvant atezolizumab with dual anti-HER2 treatment and chemotherapy in HER2-positive stage II/III breast cancer (NCT03991878, Neo-PATH). After surgery, adjuvant atezolizumab, trastuzumab and pertuzumab is administered in patients achieving pCR; adjuvant atezolizumab and T-DM1 is administered in patients not achieving pCR. Because atezolizumab showed an overall pCR rate of 61.2% with a modest toxicity profile, further research is needed regarding incorporation of atezolizumab. Several trials are currently evaluating incorporation of immunotherapy in HER2-positive early breast cancer patients.

Trials tailored to various situations
There is an ongoing de-escalating trial evaluating neoadjuvant taxane and dual anti-HER2 agents of pertuzumab and trastuzumab and adjuvant dual anti-HER2 agents in stage II–IIIA breast cancer patients who achieve pCR or adjuvant T-DM1 who do not achieve pCR (NCT04266249, CompassHER2-pCR trial). In the CompassHER2 Residual Disease trial as an extension, residual disease patients who did not achieve pCR after neoadjuvant taxane and dual anti-HER2 targeting of pertuzumab and trastuzumab in stage II–IIIA breast cancer are randomized to a group of T-DM1 versus a group of T-DM1 and another HER2-targeting oral tyrosine kinase inhibitor, tucatinib. IDFS is the primary endpoint (NCT04457596). In addition, the role of pan-HER2 inhibitors such as tucatinib in neoadjuvant chemotherapy needs to be determined. Another similar de-escalating trial evaluating a combined subcutaneous fixed dose combination (FDC) of pertuzumab and trastuzumab is ongoing. After neoadjuvant dual anti-HER2 treatment and surgery, adjuvant pertuzumab and trastuzumab subcutaneous FDC or adjuvant T-DM1 with or without anthracycline-based chemotherapy is administered depending on RCB score (NCT04675827, Decrescendo trial).
The ongoing randomized phase II ATEMPT 2.0 trial, which compares adjuvant T-DM1 followed by trastuzumab versus paclitaxel and trastuzumab followed by trastuzumab in stage I HER2-positive invasive breast cancer patients seeks to determine whether T-DM1 followed by trastuzumab will have fewer side effects and better clinical benefits (NCT04893109).

Moreover, there is an ongoing phase II trial to omit surgery in low-risk HER2-positive early breast cancer patients. In HER2-enriched/ERBB2-high breast cancer patients according to PAM50 intrinsic subtype, loco-regional surgery is omitted if there is a complete response after dual anti-HER2 neoadjuvant therapy of paclitaxel, trastuzumab, and pertuzumab (NCT04578106, ELPIS trial).

### Table 3. Ongoing perioperative anti-HER2 and immune-oncology trials.

| Trials | Setting | Phase | Study description |
|--------|---------|-------|-------------------|
| **Neoadjuvant anti-HER2 treatment** | | | |
| NCT05113251 | Neoadjuvant | III | Neoadjuvant T-DXd for eight cycles versus T-DXd for four cycles followed by paclitaxel, trastuzumab, and pertuzumab versus anthracycline and cyclophosphamide for four cycles followed by paclitaxel, trastuzumab, and pertuzumab in locally advanced or inflammatory HER2+ breast cancer patients |
| **Adjuvant anti-HER2 treatment** | | | |
| NCT04893109 | Adjuvant | II | Adjuvant T-DM1 followed by trastuzumab versus paclitaxel and trastuzumab followed by trastuzumab in stage I HER2+ breast cancer patients |
| NCT04266249 | Neoadjuvant ~ Adjuvant | II | Neoadjuvant taxane, trastuzumab, and pertuzumab in stage II-IIIA HER2+ breast cancer patients followed by adjuvant trastuzumab and pertuzumab if pCR is achieved or followed by adjuvant T-DM1 if pCR is not achieved |
| NCT04675827 | Neoadjuvant ~ Adjuvant | II | Neoadjuvant taxane combined with SC FDC of pertuzumab and trastuzumab followed by adjuvant SC FDC of pertuzumab and trastuzumab if pCR is achieved or followed by adjuvant T-D1 if RCB score is 1 or followed by adjuvant anthracycline-based chemotherapy and T-DM1 if RCB score is 2 or greater in HER2+/ER-/node-negative early breast cancer patients |
| **Adjuvant anti-HER2 treatment for non-pCR patients** | | | |
| NCT04622319 | Adjuvant | III | Adjuvant T-DXd versus T-DM1 in HER2+ breast cancer patients with residual disease following neoadjuvant therapy |
| NCT04457596 | Adjuvant | III | Adjuvant T-DM1 and placebo versus T-DM1 and tucatinib in residual disease patients who did not achieve pCR in stage II-IIIA HER2+ breast cancer |
| **Immune checkpoint inhibitors** | | | |
| NCT04873362 | Adjuvant | III | Adjuvant atezolizumab or placebo and T-DM1 in HER2+ breast cancer patients at high risk of recurrence following preoperative therapy |
| NCT03991878 | Neoadjuvant ~ Adjuvant | IB-II | Neoadjuvant atezolizumab, docetaxel, trastuzumab, and pertuzumab followed by adjuvant atezolizumab, trastuzumab, and pertuzumab versus atezolizumab and T-DM1 depending on pCR status in HER2+ breast cancer patients |
| **Omitting surgery** | | | |
| NCT04578106 | Omitting surgery | II | Omitting surgery in low-risk HER2+ early breast cancer patients if there is a complete response after standard anti-HER2-based neoadjuvant therapy with paclitaxel, trastuzumab, and pertuzumab |

HER2+, human epidermal growth factor receptor 2 positive; pCR, pathologic complete response; RCB, residual cancer burden; SC FDC, subcutaneous fixed dose combination; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
Discussion

As of 2021, pCR rates are approximately 60% or more, and long-term outcomes are correlated with pCR rates in HER2-positive breast cancer patients. Thus, neoadjuvant treatment with HER2 targeting is preferred in HER2-positive early breast cancer patients if the tumor is larger than 2 cm. To improve outcomes, several clinical trials are ongoing, and there is much attention on the Destiny-Breast11 trial incorporating T-DXd in the neoadjuvant setting based on the promising results of its use in metastatic settings.

After groundbreaking development of trastuzumab for HER2-positive breast cancer patients, subsequent novel drugs such as pertuzumab, neratinib, T-DM1, and T-DXd have been developed and used in various settings alone or in combination. In addition, immune checkpoint inhibitors are under investigation to improve the outcomes. To achieve higher pCR rates in early HER2-positive breast cancer patients and lower recurrence and progression rates in patients with residual disease, relevant data are accumulating. The current anti-HER2 treatment strategy is likely to change depending on the results of ongoing and planned clinical trials. In the future, tailored treatments such as no adjuvant therapy, various HER2-directed therapies alone with chemotherapy, combinations of various HER2-directed therapies and chemotherapy, addition of immune checkpoint inhibitors, and omission of surgery will be individualized in HER2-positive early breast cancer patients (Figure 2).

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Author contributions

Joohyun Hong: Conceptualization; Writing – original draft; Writing – review & editing; Visualization.

Yeon Hee Park: Conceptualization; Project administration; Writing – review & editing; Supervision; Visualization.

ORCID iD

Joohyun Hong https://orcid.org/0000-0003-1796-0334

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement

The authors declare that there is no conflict of interest.

Availability of data and materials

Not applicable.

References

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182.

2. Hurvitz SA, Hu Y, O’Brien N, et al. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2013; 39: 219–229.

3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792.

4. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–726.

Figure 2. Tailored treatment for HER2+ early breast cancer. HER2+, human epidermal growth factor receptor 2 positive.
15. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors ≥1 cm or smaller. *J Clin Oncol* 2009; 27: 5700–5706.

16. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. *J Clin Oncol* 2008; 26: 5697–5704.

17. Park YH, Kim ST, Cho EY, et al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? *Breast Cancer Res Treat* 2010; 119: 653–661.

18. McArthur HL, Mahoney KM, Morris PG, et al. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. *Cancer* 2011; 117: 5461–5468.

19. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. *N Engl J Med* 2015; 372: 134–141.

20. Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 2019; 37: 1868–1875.

21. Goel AK, Zamre V, Chaudhary P, et al. APT trial: would it really help in de-escalation of therapy? *J Clin Oncol* 2019; 37: 2953–2954.

22. Conte P, Frassoldati A, Bisagni G, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized short-HER study. *Ann Oncol* 2018; 29: 2328–2333.

23. Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. *JAMA Oncol* 2018; 4: 1199–1206.

24. Mavroudis D, Saloustros E, Malamos N, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). *Ann Oncol* 2015; 26: 1333–1340.

25. Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. *Lancet* 2019; 393: 2991–2998.
26. Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393: 2599–2612.

27. Ponde N, Gelber RD and Piccart M. PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? NPJ Breast Cancer 2019; 5: 1.

28. Geyer CE, Forster J, Lindquist D, et al. Laptatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–2743.

29. Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant laptatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase iii adjuvant laptatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2016; 34: 1034–1042.

30. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010; 28: 1301–1307.

31. Martin M, Bonneterre J, Geyer CE Jr, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 2013; 49: 3763–3772.

32. Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17: 367–377.

33. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18: 1688–1700.

34. Chan A, Moy B, Mansi J, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer 2021; 21: 80–91.e87.

35. Barcenas CH, Hurvitz SA, Di Palma JA, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol 2020; 31: 1223–1230.

36. Baselga J and Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463–475.

37. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109–119.

38. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724–734.

39. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377: 122–131.

40. Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol 2021; 39: 1448–1457.

41. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1194–1220.

42. National Comprehensive Cancer Network. Breast cancer (version 2.2022), (2021) https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

43. Barok M, Joensuu H and Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 2014; 16: 209.

44. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783–1791.

45. Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 732–742.

46. Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 689–699.

47. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617–628.

48. Loibl S, Huang C, Mano MS, et al. 96O adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer.
cancer: subgroup analysis from KATHERINE. *Ann Oncol* 2020; 31: S48.

49. Mamounas EP, Untch M, Mano MS, *et al.* Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. *Ann Oncol* 2021; 32: 1005–1014.

50. Tolaney SM, Tayob N, Dang C, *et al.* Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. *J Clin Oncol* 2021; 39: 2375–2385.

51. Harbeck N, Im SA, Barrios CH, *et al.* Primary analysis of KAITLIN: a phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). *J Clin Oncol* 2020; 38: 500.

52. Strasser-Weippl K, Horick N, Smith IE, *et al.* Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. *Breast Cancer Res* 2015; 17: 56.

53. Untch M, Gelber RD, Jackisch C, *et al.* Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. *Ann Oncol* 2008; 19: 1090–1096.

54. Francis PA, Pagani O, Fleming GF, *et al.* Tailoring adjuvant endocrine therapy for premenopausal breast cancer. *N Engl J Med* 2018; 379: 122–137.

55. Peleg Hassan S, Brezis MR, Shachar E, *et al.* Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis. *ESMO Open* 2021; 6: 100088.

56. Mieog JS, van der Hage JA and van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. *Br J Surg* 2007; 94: 1189–1200.

57. von Minckwitz G, Untch M, Blohmer JU, *et al.* Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 2012; 30: 1796–1804.

58. Untch M, Fasching PA, Koncency GE, *et al.* Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. *J Clin Oncol* 2011; 29: 3351–3357.

59. Cortazar P, Zhang L, Untch M, *et al.* Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* 2014; 384: 164–172.

60. Broglio KR, Quintana M, Foster M, *et al.* Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. *JAMA Oncol* 2016; 2: 751–760.

61. Houssami N, Macaskill P, von Minckwitz G, *et al.* Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. *Eur J Cancer* 2012; 48: 3342–3354.

62. Gianni L, Eiermann W, Semiglazov V, *et al.* Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet* 2010; 375: 377–384.

63. Gianni L, Eiermann W, Semiglazov V, *et al.* Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet Oncol* 2014; 15: 640–647.

64. Baselga J, Bradbury I, Eidtmann H, *et al.* Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. *Lancet* 2012; 379: 633–640.

65. Huober J, Holmes E, Baselga J, *et al.* Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. *Eur J Cancer* 2019; 118: 169–177.

66. Haagensen J, Frassoldati A, Bottini A, *et al.* Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. *J Clin Oncol* 2012; 30: 1989–1995.

67. Guarnieri V, Frassoldati A, Bottini A, *et al.* Lapatinib with trastuzumab as neoadjuvant therapy for HER2-positive early breast cancer: survival analyses of the CHER-Lob trial. *Eur J Cancer* 2021; 153: 133–141.

68. Carey LA, Berry DA, Ollila D, *et al.* Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. *J Clin Oncol* 2013; 31: 500.
69. Fernandez-Martinez A, Krop IE, Hillman DW, et al. Survival, pathologic response, and genomics in CALGB 40601 (alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer. J Clin Oncol 2020; 38: 4184–4193.

70. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17: 791–800.

71. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25–32.

72. Schneweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278–2284.

73. Schneweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 2018; 89: 27–35.

74. Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 2018; 29: 646–653.

75. Dang C, Ewer MS, Delaloge S, et al. 430 – pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE. Ann Oncol 2021; 32: S37–S47.

76. Loibl S, Jackisch C, Schneweiss A, et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol 2017; 28: 497–504.

77. Schneweiss A, Möbus V, Tesch H, et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. Eur J Cancer 2019; 106: 181–192.

78. van Ramshorst MS, van Werkhoven E, Honkoop AH, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: the TRAIN-2 study. Breast 2016; 29: 153–159.

79. van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018; 19: 1630–1640.

80. van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol 2021; 7: 978–984.

81. Nitz UA, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. Ann Oncol 2017; 28: 2768–2772.

82. Pérez-García JM, Gebhart G, Ruiz Borrego M, et al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol 2021; 22: 858–871.

83. Clark AS, Yau C, Wolf DM, et al. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/ pertuzumab for HER2(+)/HR- breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun 2021; 12: 6428.

84. Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2018; 19: 115–126.
85. Hatschek T, Foukakis T, Bjohle J, et al. Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: a phase 2 randomized clinical trial. *JAMA Oncol* 2021; 7: 1360–1367.

86. Hurvit SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. *J Clin Oncol* 2019; 37: 2206–2216.

87. Filho OM, Viale G, Stein S, et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. *Ann Oncol* 2021; 11: 2474–2487.

88. Huober J, Barrios CH, Niikura N, et al. VP6-2021: Impassion050: a phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoad) A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC). *Ann Oncol* 2021; 32: 1061–1062.

89. Loibl S, Majewski I, Guarneri V, et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. *Ann Oncol* 2016; 27: 1519–1525.

90. Goel S and Krop IE. PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum. *Ann Oncol* 2016; 27: 1368–1372.

91. Solinas C, Ceppi M, Lambertini M, et al. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta-analysis of randomized controlled trials. *Cancer Treat Rev* 2017; 57: 8–15.

92. Luen SJ, Griguolo G, Nuciforo P, et al. On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome. *J Clin Oncol* 2019; 37: 574.

93. Hamy AS, Pierga JY, Sabaila A, et al. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. *Ann Oncol* 2017; 28: 2233–2240.

94. Park YH, Lal S, Lee JE, et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. *Nat Commun* 2020; 11: 6175.

95. Schettini F, Pascual T, Conte B, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. *Cancer Treat Rev* 2020; 84: 101965.

96. Prat A, Pascual T, De Angelis C, et al. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. *J Natl Cancer Inst* 2020; 112: 46–54.

97. Harbeck N, Gluz O, Christgen M, et al. De-escalated neoadjuvant pertuzumab + trastuzumab with or without paclitaxel weekly in HR–HER2+ early breast cancer: ADAPT-HR–HER2+ biomarker and survival results. *Journal of Clinical Oncology* 2021; 39: 503.

98. Graeser M, Gluz O, Biehl C, et al. LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial. *Ann Oncol* 2021; 32: S48.

99. Ogitani Y, Hagihara K, Oitate M, et al. Impact of HER2 receptor 2-positive breast cancer: three-year outcomes from the randomized phase III stochastic trial of lapatinib and trastuzumab with or without paclitaxel weekly in HR–HER2+ early breast cancer: ADAPT-HR–HER2+ biomarker and survival results. *Journal of Clinical Oncology* 2021; 39: 503.

100. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med* 2020; 382: 610–621.

101. Cortés J, Kim SB, Chung WP, et al. LBA1 DESTINY-Breast03 study. *Ann Oncol* 2021; 32: S1287–S1288.

102. Park YH, Im SA, Sim SH, et al. 124P Phase Ib–II neoadjuvant chemotherapy with docetaxel plus atezolizumab plus herceptin SC and pertuzumab (TAHP) for patients with HER2-positive stage II/III breast cancer (Neo-PATH) (KCSG BR 18-23, NCT03991878). *Ann Oncol* 2021; 32: S412.